Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience

Original Research

(2203) Views  (501) Full article downloads

Authors: Tatiana de Melo Gomes de Oliveira, Ana Patricia Peres Fiore, Yára Dadalti Fragoso

Published Date March 2008 Volume 2008:2 Pages 41 - 46

DOI: http://dx.doi.org/10.2147/PPA.S2255

Tatiana de Melo Gomes de Oliveira¹, Ana Patricia Peres Fiore², Yára Dadalti Fragoso²

¹TEVA Pharmaceutical, Brazil; ²Medical School of Universidade Metropolitana de Santos and Reference Center for Multiple Sclerosis of the coastal region of the State of São Paulo (DRS-IV), Brazil

Abstract: Multiple sclerosis is a chronic disease characterized by demyelination and neurodegeneration of the central nervous system. Immunomodulatory treatment is possible at an early stage of the disease, and consists of injections of either beta-interferon or glatiramer acetate. The drugs are not curative, and the need for frequent injections may give rise to a serious problem regarding adherence to treatment. The present study analyzed the database of all Brazilian patients using glatiramer acetate between June 2003 and December 2006 who had enrolled in the patient program run by the pharmaceutical company commercializing the drug. The rate of treatment discontinuation was 10% over this period, and the main reason for suspending the drug was medical decisions (47% of all discontinuations), rather than side effects or the patient’s choice. The present work did not take into consideration the regularity of injections and the main objective was to assess discontinuation. It was concluded that adequate healthcare, education, and a specific program for patients were the factors responsible for this 90% adherence to glatiramer acetate treatment in Brazil.

Keywords: multiple sclerosis, glatiramer acetate, adherence